ArticleMolecular therapy oncolytics2016
Development of new therapy for canine mammary cancer with recombinant measles virus.
Article in Molecular therapy oncolytics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Canine Mammary Tumors: Classification, Biomarkers, Traditional and Personalized Therapies.International journal of molecular sciences · 2024Review
- Anti-cancer effects of DHP107 on canine mammary gland cancer examined through in-vitro and in-vivo mouse xenograft models.BMC veterinary research · 2024Article
- Anti-tumor activity of a recombinant measles virus against canine lung cancer cells.Scientific reports · 2023Article
- Investigation of oncolytic effect of recombinant Newcastle disease virus in primary and metastatic oral melanoma.Medical oncology (Northwood, London, England) · 2023Article
- Tumor-Homing of Mesenchymal Stem Cells Infected with Oncolytic Virus in a Canine Patient.Veterinary sciences · 2022Article
- Decreased Size of Mammary Tumors Caused by Preoperative Treatment with Aglepristone in Female Domestic Dogs (Animals : an open access journal from MDPI · 2021Article
- From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review.Frontiers in veterinary science · 2021Review
- Recombinant SLAMblind Measles Virus Is a Promising Candidate for Nectin-4-Positive Triple Negative Breast Cancer Therapy.Molecular therapy oncolytics · 2020Article
- Review
- Pathological and genetic aspects of spontaneous mammary gland tumor in Tupaia belangeri (tree shrew).PloS one · 2020Article
- Oncolytic Viruses for Canine Cancer Treatment.Cancers · 2018Review
- The Host Cell Receptors for Measles Virus and Their Interaction with the Viral Hemagglutinin (H) Protein.Viruses · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic virotherapy is a promising treatment strategy for cancer. We previously generated a recombinant measles virus (rMV-SLAMblind) that selectively uses a poliovirus receptor-related 4 (PVRL4/Nectin4) receptor, but not signaling lymphocyte activation molecule (SLAM). We demonstrated that the virus exerts therapeutic effects against human breast cancer cells. Here, we examined the applicability of rMV-SLAMblind to treating canine mammary cancers (CMCs). We found that the susceptibilities of host cells to rMV-SLAMblind were dependent on canine Nectin-4 expression. Nectin-4 was detected in four of nine CMC cell lines. The rMV-SLAMblind efficiently infected those four Nectin-4-positive cell lines and was cytotoxic for three of them (CF33, CHMm, and CTBm). In vivo experiment showed that the administration of rMV-SLAMblind greatly suppressed the progression of tumors in mice xenografted with a CMC cell line (CF33). Immunohistochemistry revealed that canine Nectin-4 was expressed in 45% of canine mammary tumors, and the tumor cells derived from one clinical specimen were efficiently infected with rMV-SLAMblind. These results suggest that rMV-SLAMblind infects CMC cells and displays antitumor activity in vitro, in xenografts, and ex vivo. Therefore, oncolytic virotherapy with rMV-SLAMblind can be a novel method for treating CMCs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.